TrialBMJ (Clinical research ed.)2026

Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.

Rui You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.